Insights - Page 3 of 5 - Health System Readiness

News

SPARC-Europe highlights patient experience of radioligand therapy in new video

SPARC-Europe has released a video of patient testimonies to raise awareness of the benefits of radioligand therapy and outline some of the challenges to access.

Opinion

COVID-19 and health system readiness

The COVID-19 pandemic has highlighted the importance of having a prepared and robust system that can keep day-to-day healthcare functions running.

News

New templates to aid application of the Radioligand Therapy Readiness Assessment Framework

The Health Policy Partnership has published a series of templates to support independent applications of the Radioligand Therapy Readiness Assessment Framework.

Events

Conference session considers what is needed for radioligand therapy in prostate cancer

The Health Policy Partnership held a session on multidisciplinary collaboration for health system readiness at the 13th European Multidisciplinary Congress on Urological Cancers.

News

ASH 2021 poster focuses on uptake of radioimmunotherapy for lymphoma

The Health Policy Partnership has published a poster at the 63rd annual meeting of the American Society of Hematology (ASH).

Opinion

New cancer therapies: how workforce capacity impacts treatment implementation

For his guest blog, Dr Martin Rolles explores how lack of workforce planning and specialist training can be a barrier to implementing new cancer therapies.

News

Leading experts join HPP and Avalere to examine readiness for radioligand therapy in the US

The Health Policy Partnership (HPP) and Avalere Health recently held a webinar on the use of radioligand therapy and readiness for its future integration in the US.

Opinion

Neuroendocrine cancer and radioligand therapy: how patient involvement can shape the regulatory process

Nikie Jervis explores the history of regulatory approval for radioligand therapy in the UK, and the importance of patient involvement, in her guest blog.

Events

Register for the virtual event: ‘Achieving readiness for radioligand therapy in the US’

On 3 November, The Health Policy Partnership and Avalere Health are holding an online event to examine the use of radioligand therapy in the US.

Events

HPP to hold session on radioligand therapy at EMUC21

The Health Policy Partnership is hosting the session ‘Radioligand therapy: multidisciplinary collaboration for health system readiness’ at EMUC21 on 25 November.

Opinion

Breaking down the inequalities that limit access to radioligand therapy

In this guest blog, Dr John Buscombe discusses the difficulties that people with cancer have accessing radioligand therapy in the UK.

News

HPP launches policy brief at an event coinciding with ESMO 2021

HPP was thrilled to launch its new policy brief 'Fostering system readiness in cancer care' on 21 September 2021, at an event coinciding with ESMO 2021.